Organoids are emerging as a powerful asset for researchers and drug developers as they seek more efficient and accurate methods to identify promising drug candidates and predict their efficacy. The ability to generate patient-derived organoids (PDOs) opens up exciting possibilities for personalized drug screening. Organoids serve as realistic and relevant models for drug screening compared to traditional 2D cell cultures. They mimic the complexity of human organs, including their cellular composition, structure, and function, providing a more accurate representation of drug responses in the human body. This enables researchers to identify potential drug candidates more confidently, and avoid costly and time-consuming setbacks in clinical trials. The organoid services market is experiencing rapid growth owing to the increasing demand for innovative screening services. Read More - https://www.theinsightpartners.com/reports/organoids-services-market